9.4 C
New York
Sunday, May 5, 2024

Morning Market Gainers

Courtesy of Benzinga.

Related SMTX
SMTC Announces Signing The Seventh Amendment To Its Revolving Credit And Security Agreement
SMTC Corp Appoints Currie as Interim CFO, Bailey to Continue as Director and Chairman of the Board
SMTC reports FQ4 results (Seeking Alpha)

Related GBSN
Great Basin Appoints New Board Members
Great Basin Submits 510(k) Application to FDA For Group B Strep Assay
Premarket Gainers / Losers as of 9:10 am (Seeking Alpha)

SMTC Corporation (NASDAQ: SMTX) shares surged 29.13% to $1.64. SMTC reported a Q4 loss of $0.15 per share on sales of $57 million.

Great Basin Scientific, Inc. (NASDAQ: GBSN) shares jumped 29.09% to $3.1499. Great Basin reported that it has received sample-to-result molecular diagnostic testing tech patents.

Movado Group, Inc. (NYSE: MOV) shares climbed 19.24% to $30.56 after the company reported stronger-than-expected earnings for the fiscal fourth quarter and raised its quarterly dividend by 10%.

SORL Auto Parts, Inc. (NASDAQ: SORL) rose 16.85% to $3.89. SORL Auto Parts reported Q4 earnings of $0.20 per share on revenue of $63.2 million.

Ever-Glory International Group, Inc. (NASDAQ: EVK) shares jumped 12.85% to $6.50. Ever-Glory International reported 2014 EPS of $1.11 on net sales of $460.1 million.

E-Commerce China Dangdang Inc. (NYSE: DANG) shares gained 9.61% to $9.19 following report of earnings beat. Dangdang reported Q4 EPS of $0.07 on revenue of 403.7 million.

GigOptix, Inc. (NYSE: GIG) shares rose 7.01% to $1.2199. GigOptix projected Q1 sales to be 5% to 6% above the midpoint of earlier-issued guidance range of $8.5 million to $8.7 million.

Charter Communications, Inc. (NASDAQ: CHTR) shares jumped 6.86% to $195.98 after the company announced its plans to acquire Bright House for $10.4 billion.

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) shares rose 6.65% to $9.14 following announcement that the company has won a federal contract for BCX-4430.

GW Pharmaceuticals plc (NASDAQ: GWPH) shares surged 1.75% to $89.95. GW Pharma has initiated the Phase 3 pivotal trial for Epidiolex in Dravet syndrome.

Posted-In: Market GainersNews Intraday Update Markets Movers

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,269FansLike
396,312FollowersFollow
2,290SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x